Prothena Corporation PLC
NASDAQ:PRTA

Watchlist Manager
Prothena Corporation PLC Logo
Prothena Corporation PLC
NASDAQ:PRTA
Watchlist
Price: 15.33 USD 0.72% Market Closed
Market Cap: 824.9m USD
Have any thoughts about
Prothena Corporation PLC?
Write Note

Prothena Corporation PLC
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Prothena Corporation PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Prothena Corporation PLC
NASDAQ:PRTA
Operating Income
-$168.2m
CAGR 3-Years
N/A
CAGR 5-Years
-14%
CAGR 10-Years
-45%
Alkermes Plc
NASDAQ:ALKS
Operating Income
$436.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amarin Corporation PLC
NASDAQ:AMRN
Operating Income
-$43.9m
CAGR 3-Years
N/A
CAGR 5-Years
7%
CAGR 10-Years
8%
No Stocks Found

Prothena Corporation PLC
Glance View

Market Cap
824.9m USD
Industry
Biotechnology

Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.

PRTA Intrinsic Value
36.55 USD
Undervaluation 58%
Intrinsic Value
Price

See Also

What is Prothena Corporation PLC's Operating Income?
Operating Income
-168.2m USD

Based on the financial report for Sep 30, 2024, Prothena Corporation PLC's Operating Income amounts to -168.2m USD.

What is Prothena Corporation PLC's Operating Income growth rate?
Operating Income CAGR 10Y
-45%

Over the last year, the Operating Income growth was -49%.

Back to Top